Formerly called Galapagos Genomics NV Number of employees 435 (end 2015) | Founded 1999 Revenue 61 million EUR (2015) | |
Traded as Euronext: GLPGNASDAQ: GLPG Stock price GLPG (AMS) € 70.68 +0.93 (+1.33%)9 Mar, 5:35 PM GMT+1 - Disclaimer CEO Onno van de Stolpe (1999–) Profiles | ||
Fresenius medical care galapagos nv genmab top most interview questions and answers
Galapagos NV (formerly known as Galapagos Genomics) is a Belgo-Dutch pharmaceutical research company which was founded in 1999. Its headquarters are located in Mechelen and has additional locations in Leiden, Romainville and Zagreb. The CEO is the Dutchman Onno van de Stolpe.
Contents
- Fresenius medical care galapagos nv genmab top most interview questions and answers
- History
- Drugs currently under development
- References
Currently it developing drugs against rheumatoid arthritis, crohn's disease, ulcerative colitis, psoriasis, systemic lupus erythematosus and cystic fibrosis.
History
Galapagos Genomics NV was founded in 1999 as a joint venture between Crucell and Tibotec. The company later changed its name to Galapagos NV and completed its initial public offering on Euronext Amsterdam and Euronext Brussels in May 2005.
The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins.